Therapeutic options for Acinetobacter baumannii infections: an update
1University of Barcelona, Hospital Clinic, School of Medicine, Department of Clinical Microbiology, Villarroel 170, Barcelona, Spain. jvila@ub.edu
Expert Opinion on Pharmacotherapy
|October 6, 2012
Summary
Acinetobacter baumannii infections are a growing concern due to multi-drug resistance. This review explores resistance mechanisms and treatment strategies, including optimized colistin dosing and combination therapies for Acinetobacter baumannii infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Antimicrobial Resistance
Background:
- Acinetobacter baumannii infections pose significant clinical challenges due to their environmental persistence and high rates of multi-drug, extended-drug, and pandrug resistance.
- While Acinetobacter pittii and Acinetobacter nosocomialis are increasingly recognized, A. baumannii remains the most clinically relevant species in nosocomial settings.
Purpose of the Study:
- To review the molecular mechanisms underlying antimicrobial resistance in Acinetobacter baumannii.
- To discuss current and potential future therapeutic strategies for treating infections caused by multi-drug resistant A. baumannii.
Main Methods:
- Literature review focusing on molecular epidemiology of resistance.
- Analysis of current treatment guidelines and emerging therapeutic options.
Main Results:
- Carbapenem resistance necessitates increased use of colistin, with potential benefits from loading doses to achieve therapeutic levels faster.
- Combination therapies, such as imipenem/sulbactam and imipenem/colistin, show promise for treating ventilator-associated pneumonia (VAP) caused by A. baumannii.
Conclusions:
- Optimizing colistin dosing and exploring novel combination therapies are crucial for managing multi-drug resistant A. baumannii infections.
- Continued research into alternative treatment strategies is essential given the escalating antimicrobial resistance crisis.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:27Acute Pyelonephritis I: Introduction
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...